Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

BACKGROUND: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the sign...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Nakano, Kazuhiko, Ohta, Shigeyuki, Komatsu, Kenji, Kubo, Taro, Nukui, Akinori, Suzuki, Kazumi, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2012
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3305626/
https://ncbi.nlm.nih.gov/pubmed/22353627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-12-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller